Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era
Correction(s) for this article
-
Erratum
- Volume 85Issue 3European Journal of Haematology
- pages: 277-277
- First Published online: August 12, 2010
Hirokazu Nagai
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya
Search for more papers by this authorTakashi Odawara
Department of Infectious Diseases and Applied Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo
Search for more papers by this authorAtsushi Ajisawa
Division of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo
Search for more papers by this authorShotaro Hagiwara
Division of Hematology, International Medical Center of Japan, Tokyo
Search for more papers by this authorTomoyuki Watanabe
Faculty of Psychological and Physical Science, Aichi Gakuin University, Nisshin
Search for more papers by this authorTomoko Uehira
Department of Infectious Diseases, National Hospital Organization Osaka National Hospital, Osaka
Search for more papers by this authorHideki Uchiumi
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma
Search for more papers by this authorMihoko Yotsumoto
Department of Laboratory Medicine, Tokyo Medical University, Tokyo
Search for more papers by this authorToshikazu Miyakawa
Department of Hematology, Faculty of Medical and Pharmaceutical Sciences Kumamoto University, Kumamoto
Search for more papers by this authorAkira Watanabe
Division of Control and Treatment of Infectious Diseases, Chiba University Hospital, Chiba
Search for more papers by this authorToshiyuki Kambe
Department of Respiratory Medicine, Asahi General Hospital, Asahi
Search for more papers by this authorMitsuru Konishi
Center for Infectious Diseases, Nara Medical University, Nara
Search for more papers by this authorSeiji Saito
Division of Blood Transfusion Services, Hiroshima University Hospital, Hiroshima
Search for more papers by this authorSoichiro Takahama
Division of Immunology and Infectious Diseases, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka
Search for more papers by this authorMasao Tateyama
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa
Search for more papers by this authorSeiji Okada
Center for AIDS Research, Kumamoto University, Kumamoto, Japan
Search for more papers by this authorHirokazu Nagai
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya
Search for more papers by this authorTakashi Odawara
Department of Infectious Diseases and Applied Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo
Search for more papers by this authorAtsushi Ajisawa
Division of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo
Search for more papers by this authorShotaro Hagiwara
Division of Hematology, International Medical Center of Japan, Tokyo
Search for more papers by this authorTomoyuki Watanabe
Faculty of Psychological and Physical Science, Aichi Gakuin University, Nisshin
Search for more papers by this authorTomoko Uehira
Department of Infectious Diseases, National Hospital Organization Osaka National Hospital, Osaka
Search for more papers by this authorHideki Uchiumi
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma
Search for more papers by this authorMihoko Yotsumoto
Department of Laboratory Medicine, Tokyo Medical University, Tokyo
Search for more papers by this authorToshikazu Miyakawa
Department of Hematology, Faculty of Medical and Pharmaceutical Sciences Kumamoto University, Kumamoto
Search for more papers by this authorAkira Watanabe
Division of Control and Treatment of Infectious Diseases, Chiba University Hospital, Chiba
Search for more papers by this authorToshiyuki Kambe
Department of Respiratory Medicine, Asahi General Hospital, Asahi
Search for more papers by this authorMitsuru Konishi
Center for Infectious Diseases, Nara Medical University, Nara
Search for more papers by this authorSeiji Saito
Division of Blood Transfusion Services, Hiroshima University Hospital, Hiroshima
Search for more papers by this authorSoichiro Takahama
Division of Immunology and Infectious Diseases, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka
Search for more papers by this authorMasao Tateyama
First Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa
Search for more papers by this authorSeiji Okada
Center for AIDS Research, Kumamoto University, Kumamoto, Japan
Search for more papers by this authorAbstract
Primary central nervous system lymphoma (PCNSL) related to acquired immunodeficiency syndrome (AIDS) is a lethal disorder, but the recent application of highly active antiretroviral therapy (HAART) has significantly improved prognosis. This retrospective cohort study of AIDS-related PCNSL examined the actual clinical outcomes and prognostic variables affecting overall survival (OS) in the HAART era. Twenty-three newly diagnosed AIDS-related PCNSL at 12 regional centre hospitals for HIV/AIDS in Japan between 2002 and 2008 were consecutively enrolled. The estimated 3-yr OS rate of the entire cohort was 64% (95%CI, 41.0–80.3%). Whole brain radiation therapy (WBRT) had an independent positive impact on survival (WBRT ≥30 Gy vs. others, P = 0.02). Nine of 10 patients with a good performance status (PS) (0–2) remained alive with complete response, whereas 10 (77%) of 13 of those with a poor PS (3–4) died mostly after a short period. The estimated 3-yr OS rate of the groups with a good and poor PS was 100% and 38% (95%CI, 14–63%), respectively (P = 0.01). Leukoencephalopathy (grade ≥ 2) developed in 21% of those that survived more than 12 months after radiation. The patients receiving a curative intent radiation dose (≥30 Gy) of WBRT achieved prolonged survival while maintaining a good quality of life in the HAART era, especially among patients with a favourable PS.
References
- 1 Gray F, Gherardi R, Scarvalli R. The neuropathology of the acquired immune deficiency syndrome (AIDS). A review. Brain 1998; 111: 245–66.
- 2 Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, Yarchoan R. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11: 1099–107.
- 3 Raez LE, Patel P, Feun L, Restrepo A, Raub WA Jr, Cassileth PA. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998; 9: 199–208.
- 4 So YT, Beckstead JH, Davis RL. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study. Ann Neurol 1986; 20: 566–72.
- 5 Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92: 1011–9.
- 6 Camilleri-Broët S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol 1997; 28: 367–74.
- 7 Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhøj P, Barton SE. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406–12.
- 8 Hishima T, Oyaizu N, Fujii T, et al. Decrease in Epstein–Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect 2006; 8: 1301–7.
- 9 Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, Rosenblum ML. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73: 206–11.
- 10 Levine A. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992; 80: 8–20.
- 11 Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093–104.
- 12
Donahue BR,
Sullivan JW,
Cooper JS.
Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma.
Cancer
1995; 76: 328–32.
10.1002/1097-0142(19950715)76:2<328::AID-CNCR2820760225>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 13 Bower M, Fife K, Sullivan A, Kirk S, Phillips RH, Nelson M, Gazzard BG. Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur J Cancer 1999; 35: 601–4.
- 14 Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15: 2119–27.
- 15 Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17: 1787–93.
- 16 Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, Millar JL, Brew BJ, Quinn DI. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004; 100: 2627–36.
- 17 Cingolani A, Fratino L, Scoppettuolo G, Antinori A. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era. J Neurovirol 2005; 11(Suppl 3): 38–44.
- 18 Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005; 46: 207–15.
- 19 Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Strbbing J. Highly active antiretroviral therapy and human immunodeficiency virus-assocated primary cerebral lymphoma. J Natl Cancer Inst 2006; 98: 1088–91.
- 20 Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Last updated: 2006. Accessed August 9, 2006.
- 21 Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994; 12: 627–42.
- 22 Conill C, Berenguer J, Vargas M, López-Soriano A, Valduvieco I, Marruecos J, Vilella R. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol 2007; 9: 590–5.
- 23 Doyle DM, Einhorn LH. Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 2008; 70: 1361–4.
- 24 Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143: 265–73.
- 25
Mead GM,
Bleehen NM,
Gregor A,
et al.
A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy.
Cancer
2000; 89: 1359–70.
10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 26 Blay YJ, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864–71.
- 27 Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144–50.
- 28 Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. Epstein–Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356: 1493–4.
- 29 Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr. AIDS Associated Malignancies Clinical Trials Consortium Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma 2006; 6: 399–402.
- 30 Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 2007; 21: 900–7.
Citing Literature
